Virtual Human Twins (VHTs) For Integrated Clinical Decision Support In Prevention And Diagnosis
HORIZON Research and Innovation Actions
Basic Information
- Identifier
- HORIZON-HLTH-2027-03-TOOL-04
- Programme
- Cluster 1 - Health (Single stage - 2027/2)
- Programme Period
- 2021 - 2027
- Status
- Forthcoming (31094501)
- Opening Date
- June 3, 2027
- Deadline
- September 22, 2027
- Deadline Model
- single-stage
- Budget
- €39,300,000
- Min Grant Amount
- €7,000,000
- Max Grant Amount
- €10,000,000
- Expected Number of Grants
- 4
- Keywords
- HORIZON-HLTH-2027-03-TOOL-04HORIZON-HLTH-2027-03Artificial intelligence, intelligent systems, multi agent systemsBasic medicineBig dataClinical medicineComputational biologyComputational modellingMachine learning, statistical data processing and applications using signal processing (e.g. speech, image, video)Medical engineering, biomedical engineering and technologyPersonalised care solutionsPersonalised interventionsPersonalised medicinePersonalised prevention
Description
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Developing and using new tools, technologies and digital solutions for a healthy society”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes:
- Healthcare professionals have access to multi-scale[1], multi-organ models of individual patients that aim to improve prevention and diagnosis in high disease burden areas.
- Health professionals benefit from enhanced knowledge of complex diseases and co-morbidities by recourse to multi-scale, multi-organ models.
- Patients with diverse characteristics (e.g. of any sex, age group, racial or ethnic origin[2]) benefit from improved, integrated and personalised prevention and diagnostics tools.
- Health professionals and patients benefit from the use of “Virtual Human Twin” (VHT) models which enable integration of other preventive and diagnostic tools and modalities.
VHTs are digital representations and in-silico models of an individual’s health and disease state at different levels of anatomy. Multi-scale, multi-organ VHT solutions have a potential for tailored prevention and diagnosis, particularly in areas of high disease burden, and can significantly benefit citizens' health and the efficiency of EU health systems.
Proposals should take into account the work of projects funded under topic HORIZON-HLTH-2023-TOOL-05-03: “Integrated, multi-scale computational models of patient patho-physiology (‘virtual twins’) for personalised disease management”, which had a predominant focus on disease management, and focus on high-potential multi-disciplinary approaches at greater complexity (multiscale, multiorgan, longitudinal), strengthening their deployment in health and care, including the integration into care pathways and links with other decision support tools.
The proposals should address all the following activities:
- Select clinical use cases to deliver multi-disciplinary, high impact solutions requiring multi-organ, multi-scale approaches to modelling complex pathophysiology over time, as a basis from where prevention and diagnosis of diseases with high morbidity and mortality could be enhanced. Proposals can put forward use cases in any areas of high disease burden; examples include co-morbidities, chronic cardiovascular conditions, infection and (auto)immunity, inflammation and cancer, diabetes and related conditions, rare diseases, degenerative diseases (including their interaction with mental health conditions), the exposome and its impact on human health and disease.
- Building on current approaches, standards, data repositories (e.g. biobanks, environmental data, others) and modelling assets (e.g. those of the EDITH CSA[3] and the Platform for Advanced VHT Models[4]), and new data if relevant, design, develop, extend and validate multi-organ, multi-scale, dynamic computational models that accurately simulate a person’s health and disease states, as necessary.
- Evaluate, select, extend and validate diverse modelling methodologies, resulting in integrated, advanced, interoperable, patient-specific VHT models that can integrate diverse data sources and methodologies, addressing the chosen clinical use case requirements. Methodologies may include and are not limited to biophysics-based modelling, artificial intelligence (AI) that should be interpretable or allow explainability of outcomes, generative AI and in-silico modelling, agent-based and network physiology approaches. Evaluation, selection and extension of these should be documented during the design phase. Availability and integration of the multi-modal data should be documented, and the ethical and sex dimensions be investigated.
- Demonstrate integration of these models with other advanced preventive and diagnostic modalities, tools and techniques enabling integration across pathways.
- Generate evidence, including clinical validation, that the solutions deliver clinically meaningful decision support, addressing use case requirements. Document lessons-learned for broader application. Gather evidence via health economic and/or feasibility studies in real-world healthcare settings confirming cost-effectiveness vis-à-vis current practice (e.g. cost-effectiveness analysis). Produce an exploitation plan on regulatory compliance[5] and intellectual property.
Proposals should be multidisciplinary; solution design and development should be end-user-focused and draw on user and non-user input. Best practice in VHT software development including responsible AI development should be followed (e.g. risk assessment and management, requirements definition process).
Participation of small and medium-sized enterprises (SMEs)[6] is encouraged.
Proposals should contribute to the objectives of the European VHT Initiative[7] and to the Platform for Advanced VHT Models, with project assets made available on the Platform and interoperable with its technical specifications[8]; relevant consortia members should join its User Community. Budget should be reserved for these activities. Projects are expected to collaborate with other EU-funded projects on VHTs[9] and align with relevant EU initiatives funded under Horizon Europe, the Digital Europe Programme[10] and the EU4Health Programme (2021-2027)[11], e.g. European Cancer Imaging Initiative[12], 1+Million Genomes Initiative[13], Intensive Care Unit Data Space[14], co-funded European Partnership for Personalised Medicine[15], and projects on advancing AI in health where relevant.
This topic requires the effective contribution of social sciences and humanities (SSH) disciplines and the inclusion of relevant SSH expertise, in order to produce meaningful and significant effects enhancing the societal impact of the related research activities.
Applicants should provide details of their clinical studies[16] in the dedicated annex using the template provided in the submission system. As proposals under this topic are expected to include clinical studies, the use of the template is strongly encouraged.
[1] In the context of this topic, multi-scale refers to modelling at different levels of human anatomy, e.g. at (sub-)cellular, tissue, organ or organ system level.
[2] The use of the term ‘racial or ethnic origin’ does not imply an acceptance of theories that attempt to determine the existence of separate human races.
[3] See the “European Virtual Human Twin” Coordination and Support Action EDITH, funded under the Digital Europe Programme: https://www.edith-csa.eu
[4] Funded under the Digital Europe Programme, procedure identifier EC-CNECT/LUX/2024/OP/0014: https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/tender-details/16cc3c6a-844a-42d4-9746-dcc7444b8001-CN
[5] For example with Regulation (EU) 2017/745 on medical devices: http://data.europa.eu/eli/reg/2017/745/oj, Regulation (EU) 2017/746 on in vitro diagnostic medical devices: http://data.europa.eu/eli/reg/2017/746/2025-01-10, Regulation (EU) 2024/1689 laying down harmonised rules on artificial intelligence: http://data.europa.eu/eli/reg/2024/1689/oj
[6] https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32003H0361
[7] https://digital-strategy.ec.europa.eu/en/policies/virtual-human-twins
[8] No contact with the developer of the Platform is required at proposal stage.
[9] Including the projects funded under topic HORIZON-HLTH-2023-TOOL-05-03: “Integrated, multi-scale computational models of patient patho-physiology (‘virtual twins’) for personalised disease management”
[10] https://digital-strategy.ec.europa.eu/en/activities/digital-programme
[11] https://commission.europa.eu/funding-tenders/find-funding/eu-funding-programmes/eu4health_en
[12] https://digital-strategy.ec.europa.eu/en/policies/cancer-imaging
[13] https://digital-strategy.ec.europa.eu/en/policies/1-million-genomes
[15] https://cordis.europa.eu/project/id/101137129, https://www.eppermed.eu
[16] Please note that the definition of clinical studies (see introduction to this Work Programme part) is broad and it is recommended that you review it thoroughly before submitting your application.
Eligibility & Conditions
General conditions
1. Admissibility Conditions, proposal page limit and layout
2. Eligible Countries
Eligible countries are described in Annex B of the Work Programme General Annexes.
A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the Horizon Europe Programme Guide.
3. Other Eligibility Conditions
In recognition of the opening of the US National Institutes of Health’s programmes to European researchers, any legal entity established in the United States of America is eligible to receive Union funding.
If projects use satellite-based earth observation, positioning, navigation and/or related timing data and services, beneficiaries must make use of Copernicus and/or Galileo/EGNOS (other data and services may additionally be used).
Subject to restrictions for the protection of European communication networks.
Other eligibility conditions are described in Annex B of the Work Programme General Annexes.
4. Financial and operational capacity and exclusion
Financial and operational capacity and exclusion are described in Annex C of the Work Programme General Annexes.
5a. Evaluation and award: Award criteria, scoring and thresholds
Award criteria, scoring and thresholds are described in Annex D of the Work Programme General Annexes.
5b. Evaluation and award: Submission and evaluation processes
The thresholds for each criterion will be 4 (Excellence), 4 (Impact) and 4 (Implementation). The cumulative threshold will be 12.
Submission and evaluation processes are described in Annex F of the Work Programme General Annexes and the Online Manual.
5c. Evaluation and award: Indicative timeline for evaluation and grant agreement
Indicative timeline for evaluation and grant agreement are described in Annex F of the Work Programme General Annexes.
6. Legal and financial set-up of the grants
The granting authority may, up to 4 years after the end of the action, object to a transfer of ownership or to the exclusive licensing of results, as set out in the specific provision of Annex 5.
Legal and financial set-up of the grants are described in Annex G of the Work Programme General Annexes.
Specific conditions
Specific conditions are described in the specific topic of the Work Programme.
Application and evaluation forms and additional documents:
Application and evaluation form templates
Standard application form (HE RIA, IA) - the application form specific to this call is available in the Submission System
Standard evaluation form (HE RIA, IA) - will be used with the necessary adaptations
Guidance
Model Grant Agreement (MGA)
Call-specific instructions
Additional documents
HE Main Work Programme 2026-2027 – 1. General Introduction
HE Main Work Programme 2026-2027 – 4. Health
HE Main Work Programme 2026-2027 – 15. General Annexes
HE Framework Programme 2021/695
HE Specific Programme Decision 2021/764
EU Financial Regulation 2024/2509
Decision authorising the use of lump sum contributions under the Horizon Europe Programme
Rules for Legal Entity Validation, LEAR Appointment and Financial Capacity Assessment
EU Grants AGA — Annotated Model Grant Agreement
Funding & Tenders Portal Online Manual
Frequently Asked Questions About Virtual Human Twins (VHTs) For Integrated Clinical Decision Support In Prevention And Diagnosis
Support & Resources
Online Manual is your guide on the procedures from proposal submission to managing your grant.
Horizon Europe Programme Guide contains the detailed guidance to the structure, budget and political priorities of Horizon Europe.
Funding & Tenders Portal FAQ – find the answers to most frequently asked questions on submission of proposals, evaluation and grant management.
Research Enquiry Service – ask questions about any aspect of European research in general and the EU Research Framework Programmes in particular.
National Contact Points (NCPs) – get guidance, practical information and assistance on participation in Horizon Europe. There are also NCPs in many non-EU and non-associated countries (‘third-countries’).
Enterprise Europe Network – contact your EEN national contact for advice to businesses with special focus on SMEs. The support includes guidance on the EU research funding.
IT Helpdesk – contact the Funding & Tenders Portal IT helpdesk for questions such as forgotten passwords, access rights and roles, technical aspects of submission of proposals, etc.
European IPR Helpdesk assists you on intellectual property issues.
CEN-CENELEC Research Helpdesk and ETSI Research Helpdesk – the European Standards Organisations advise you how to tackle standardisation in your project proposal.
The European Charter for Researchers and the Code of Conduct for their recruitment – consult the general principles and requirements specifying the roles, responsibilities and entitlements of researchers, employers and funders of researchers.
Partner Search help you find a partner organisation for your proposal.
Latest Updates
No updates available.